In situ Detecting Lipids as Potential Biomarkers for the Diagnosis and Prognosis of Intrahepatic Cholangiocarcinoma

References

• Poultsides GA, Zhu AX, Choti MA, et al. Intrahepatic cholangiocarcinoma. J Am Coll Surg. 2010;90:817–837.
   Google Scholar
• Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149:565. doi:10.1001/jamasurg.2013.5137
   PubMed Web of Science ®Google Scholar
• Mosadeghi S, Liu B, Bhuket T, et al. Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the U.S.: an updated analysis of the 2000–2011 surveillance, epidemiology, and end results registry. Hepatol Res. 2016;46:669–677. doi:10.1111/hepr.12605
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21:594–599. doi:10.1634/theoncologist.2015-0446
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Frega G, Ricci AD, et al. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis. Vivo. 2020;34:479–488. doi:10.21873/invivo.11798
   PubMed Web of Science ®Google Scholar
• Massa A, Varamo C, Vita F, et al. Evolution of the experimental models of cholangiocarcinoma. Cancers. 2020;12:2308. doi:10.3390/cancers12082308
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Pemigatinib: hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun. 2021;27:100337. doi:10.1016/j.ctarc.2021.100337
   PubMedGoogle Scholar
• Arentz G, Mittal P, Zhang C, et al. Applications of mass spectrometry imaging to cancer. Adv Cancer Res. 2017;134:27–66.
   PubMed Web of Science ®Google Scholar
• Cho WC. Mass spectrometry-based proteomics in cancer research. Expert Rev Proteomics. 2017;14:725–727. doi:10.1080/14789450.2017.1365604
   PubMed Web of Science ®Google Scholar
• Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013;144:1066–1075 e1. doi:10.1053/j.gastro.2013.01.054
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Coukos G. Mass spectrometry-based antigen discovery for cancer immunotherapy. Curr Opin Immunol. 2016;41:9–17. doi:10.1016/j.coi.2016.04.005
   PubMed Web of Science ®Google Scholar
• Chen G, Li H, Qiu L, et al. Change of fucosylated IgG2 Fc-glycoforms in pancreatitis and pancreatic adenocarcinoma: a promising disease-classification model. Anal Bioanal Chem. 2014;406:267–273. doi:10.1007/s00216-013-7439-3
   PubMed Web of Science ®Google Scholar
• Balluff B, Hanselmann M, Heeren RM. Mass spectrometry imaging for the investigation of intratumor heterogeneity. Adv Cancer Res. 2017;134:201–230.
   PubMed Web of Science ®Google Scholar
• Han EC, Lee YS, Liao WS, et al. Direct tissue analysis by MALDI-TOF mass spectrometry in human hepatocellular carcinoma. Clin Chim Acta. 2011;412:230–239. doi:10.1016/j.cca.2010.09.021
   PubMed Web of Science ®Google Scholar
• Faouder JL, Gigante E, Léger T, et al. Proteomic landscape of cholangiocarcinomas reveals 3 different subgroups according to their localization and the aspect of non-tumor liver. Proteomics. 2019;13:1800128.
   Web of Science ®Google Scholar
• Lankisch TO, Jochen M, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Gastroenterology. 2011;140:875–884. doi:10.1016/S0016-5085(11)60273-4
   Web of Science ®Google Scholar
• Farid SG, Craven RA, Jianhe P, et al. Shotgun proteomics of human bile in hilar cholangiocarcinoma. Proteomics. 2011;11:2134–2138. doi:10.1002/pmic.201000653
   PubMed Web of Science ®Google Scholar
• Reid S, Tibshirani R, Friedman J. A study of error variance estimation in lasso regression. Stat Sin. 2013;2013:35–67.
   Google Scholar
• Dos Santos A, Court M, Thiers V, et al. Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol Cell Proteom. 2010;9:1991–2004
   PubMed Web of Science ®Google Scholar
• Wang X, Dai S, Zhang Z, et al. Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care. 2009;18:625–635. doi:10.1111/j.1365-2354.2008.00965.x
   PubMed Web of Science ®Google Scholar
• Le Faouder J, Laouirem S, Alexandrov T, et al. Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry. Proteomics. 2014;14:965–972. doi:10.1002/pmic.201300463
   PubMed Web of Science ®Google Scholar
• Park YS, Chong WY, Lee SC, et al. Lipid profiles for intrahepatic cholangiocarcinoma identified using matrix-assisted laser desorption/ionization mass spectrometry. Clinica Chimica Acta. 2011;412:1978–1982. doi:10.1016/j.cca.2011.07.008
   PubMed Web of Science ®Google Scholar
• Poli A, Billi AM, Mongiorgi S, et al. Nuclear phosphatidylinositol signaling: focus on phosphatidylinositol phosphate kinases and phospholipases C. J Cell Physiol. 2016;231:1645–1655. doi:10.1002/jcp.25273
   PubMed Web of Science ®Google Scholar
• Weber GF, Menko AS. Phosphatidylinositol 3-kinase is necessary for lens fiber cell differentiation and survival. Invest Ophthalmol Vis Sci. 2006;47:4490–4499. doi:10.1167/iovs.06-0401
   PubMed Web of Science ®Google Scholar
• Barberino RS, Santos JMS, Lins T, et al. Epigallocatechin-3-gallate (EGCG) reduces apoptosis of preantral follicles through the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) signaling pathway after in vitro culture of sheep ovarian tissue. Theriogenology. 2020;155:25–32. doi:10.1016/j.theriogenology.2020.05.037
   PubMed Web of Science ®Google Scholar
• Zewe JP, Miller AM, Sangappa S, et al. Probing the subcellular distribution of phosphatidylinositol reveals a surprising lack at the plasma membrane. J Cell Biol. 2020;219. doi:10.1083/jcb.201906127
   PubMed Web of Science ®Google Scholar
• Kuna RS, Field SJ. GOLPH3: a Golgi phosphatidylinositol(4)phosphate effector that directs vesicle trafficking and drives cancer. J Lipid Res. 2019;60:269–275. doi:10.1194/jlr.R088328
   PubMed Web of Science ®Google Scholar
• Kurz M, Brachvogel V, Matter H, et al. Insights into the bile acid transportation system: the human ileal lipid-binding protein-cholyltaurine complex and its comparison with homologous structures. Proteins Struct Funct Bioinform. 2010;50:312–328. doi:10.1002/prot.10289
   Web of Science ®Google Scholar
• Qiu Y, Zhou B, Su M, et al. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. Int J Mol Sci. 2013;14:8047–8061. doi:10.3390/ijms14048047
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Weljie AM, Kopciuk KA, et al. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br J Cancer. 2016;115:848–857. doi:10.1038/bjc.2016.243
   PubMed Web of Science ®Google Scholar
• Lassman ME, Mcavoy T, Chappell DL, et al. The clinical utility of mass spectrometry based protein assays. Clinica Chimica Acta. 2016;459:155–161. doi:10.1016/j.cca.2016.05.027
   PubMed Web of Science ®Google Scholar
• Olivier F, David F, Yves-Patrice LT, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer. 2011;117:2170–2177. doi:10.1002/cncr.25712
   PubMed Web of Science ®Google Scholar
• Wurlitzer M, Hessling E, Rinas K, et al. Mass spectrometric lipid profiles of picosecond infrared laser-generated tissue aerosols discriminate different brain tissues. Lasers Surg Med. 2020;52:228–234. doi:10.1002/lsm.23096
   PubMed Web of Science ®Google Scholar
• Lapitz A, Arbelaiz A, O’Rourke CJ, et al. Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis. Cells. 2020;9:721. doi:10.3390/cells9030721
   PubMed Web of Science ®Google Scholar
• Wolrab D, Jirásko R, Cífková E, et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat Commun. 2022;13:124. doi:10.1038/s41467-021-27765-9
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tavolari S, et al. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020;17:441–452. doi:10.21873/cgp.20203
   PubMed Web of Science ®Google Scholar